导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.30% | 2783/4773 |
| 近一周 | -1.83% | 2967/5465 |
| 近一月 | -3.52% | 2593/5421 |
| 近一季 | -6.75% | 2536/5231 |
| 近半年 | -2.10% | 2007/4920 |
| 近一年 | 1.07% | 2571/4394 |
| 近两年 | 45.10% | 1670/2954 |
| 近三年 | 28.41% | 1150/2253 |
| 成立以来 | 45.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.49% 3241/4961 |
11.84% 2286/5312 |
- - |
- - |
| 2025 | 19.27% 2234/4813 |
-0.87% 2442/3635 |
2.26% 1706/4076 |
17.70% 2449/4524 |
-0.03% 2316/4813 |
| 2024 | 16.92% 745/3463 |
2.94% 661/2808 |
-1.10% 933/3014 |
16.45% 1450/3129 |
-1.37% 1673/3463 |
| 2023 | -8.41% 1012/2656 |
4.28% 999/2280 |
-3.82% 916/2385 |
-2.58% 698/2515 |
-6.25% 1694/2655 |
| 2022 | -18.72% 746/2207 |
-13.62% 800/1919 |
6.73% 622/2016 |
-13.25% 868/2113 |
1.64% 1194/2208 |
| 2021 | 2.02% 642/1822 |
-2.35% 627/1255 |
6.49% 741/1330 |
-3.67% 652/1466 |
1.85% 780/1822 |
| 2020 | 35.55% 410/1250 |
-10.08% 749/1028 |
13.22% 637/1067 |
16.02% 176/1164 |
14.75% 250/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 民生加银沪深300ETF联接A VS. 长安沪深300非周期A(740101) |